Stage (next event)
December 7, 2020
Catalyst Info & Data Links
TITLE: Rivipansel (GMI-1070) for SCD - Acute Vaso-Occlusive Crisis (VOC) - Phase 3
ClinicalTrial.gov (NCT02187003): Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease
WHAT IS THE NEXT CATALYST EVENT?
FDA Guidance on Next Steps
ASH Detailed meeting
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
December 7th, 2020 (ASH Meeting)
2020 Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: RESET Clinical Trial Analysis.
Mechanism of Action
MECHANISM OF ACTION
Updated by JM
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post